For a report overview of this report please contact sara.peerun@visiongainglobal.com (+44 (0) 20 7336 6100) or refer to our website: https://www.visiongain.com/ https://www.visiongain.com/Report/1830/Global-Inflammatory-Bowel-Diseases-(IBD)-Drug-Market-Forecast-2017-2027

1. ©notice
This material is copyright by visiongain. It is against the law to reproduce any of this material without the prior
written agreement of visiongain.You cannot photocopy, fax, download to database or duplicate in any other way
any of the material contained in this report. Each purchase and single copy is for personal use only.
Global Inflammatory Bowel Diseases
(IBD) Drug Market Forecast 2017-2027
Aminosalicylates, Antibiotics, Corticosteroids, Immunomodulators, Biologics,
Crohn’s Disease, Ulcerative Colitis

2. www.visiongain.com
Contents
1. Report Overview
1.1 World IBD Drugs Market: Overview of Findings
1.2 Why You Should Read This Report
1.3 How the Study Delivers
1.4 Main Questions Covered in the Analysis
1.5 Who Is This Report For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Reports
1.9 About Visiongain
2. Introduction to the Inflammatory Bowel Disease Drug Market
2.1 What is Inflammatory Bowel Disease (IBD)?
2.2 Classification of IBD
2.3 Symptoms and Diagnosis of IBD
2.4 Multifactorial Causes of IBD
2.5 How Common is IBD?
2.6 What Are the Treatment Options for IBD?
2.6.1 Aminosalicylates – The Most Common therapy
2.6.2 Antibiotics – Will There Be Any Supporting Evidence Soon?
2.6.3 Corticosteroids – Uptake from Uceris?
2.6.4 Immunomodulators – Slow to Act?
2.6.5 Monoclonal Antibodies – Not cost-effective?
2.7 Treatment Goals for IBD – Treat-to-Target Approach?
2.8 Treatment Algorithm – is Top-Down Approach the Future Direction?

3. www.visiongain.com
Contents
3. The World Inflammatory Bowel Disease Drug Market, 2017-2027
3.1 The Inflammatory Bowel Disease Market in 2016 and 2017
3.2 Forecast 2017-2027: Impacted by Biosimilars?
3.3 Biologic Therapies Forecast 2017-2027 – Driving the Market
3.4 Aminosalicylates Forecast 2017-2027: The Work Horse of IBD Market
3.5 Antibiotics Forecast 2017-2027: Growing Despite Challenges
3.6 Corticosteroids Forecast 2017-2027: Driven by Uceris
3.7 Immunomodulators Forecast 2017-2027 – Will Slowly Lose Market Share
4. Market Prospects for Leading IBD Drugs, 2017-2027
4.1 Humira (AbbVie) – Growing in the First Half of Forecast Period
4.1.1 Humira: Forecast and Analysis, 2017-2027
4.2 Remicade (Janssen Biotech) – Will Slowly be Eroded by Biosimilars
4.2.1 Remicade: Forecast and Analysis, 2017-2027
4.3 Asacol (Allergan) – Threat from Generic Competition
4.3.1 Asacol: Forecast and Analysis, 2017-2027
4.4 Pentasa (Shire) – Differentiated by Its Delivery System
4.4.1 Pentasa: Forecast and Analysis, 2017-2027
4.5 Lialda (Shire) – Will Improved Compliance Increase Revenue?
4.5.1 Lialda: Forecast and Analysis, 2017-2027
4.6 Tysabri (Perrigo) – Still Protected by Patent
4.6.1 Tysabri: Forecast and Analysis, 2017-2027
4.7 Xifaxan (Valeant) – Still Growing Significantly
4.7.1 Xifaxan: Forecast and Analysis, 2017-2027
4.8 Cimzia (UCB) – How Will It Fare Against Biosimilars?
4.8.1 Cimzia: Forecast and Analysis, 2017-2027
4.9 Entocort (AstraZeneca) – A Slow and Steady Decline?
4.9.1 Entocort: Forecast and Analysis, 2017-2027
4.10 Neoral (Novartis) – Will its Side Effect Profile Hamper Sales Growth?
4.10.1 Neoral: Forecast and Analysis, 2017-2027

4. www.visiongain.com
Contents
4.11 Medrol (Pfizer) – Another Leading Steroid
4.11.1 Medrol: Forecast and Analysis, 2017-2027
4.12 Canasa (Allergan) – Will a Generic Competitor Soon Be Available?
4.12.1 Canasa/Salofalk: Forecast and Analysis, 2017-2027
4.13 Apriso (Valeant) – Challenger to Asacol?
4.13.1 Apriso: Forecast and Analysis, 2017-2027
4.14 Azulfidine (Pfizer) – Tried, Tested and Staying in the Market
4.14.1 Azulfidine: Forecast and Analysis, 2017-2027
4.15 Entyvio (Takeda Pharmaceuticals) – Driving the Biologics Segment
4.15.1 Entyvio: Forecast and Analysis, 2017-2027
4.16 Simponi (Janssen Biotech) – Rising Star for the Market?
4.16.1 Simponi: Forecast and Analysis, 2017-2027
4.17 Uceris (Valeant) – Meeting Patients’ Needs with Its Delivery System
4.17.1 Uceris: Forecast and Analysis, 2017-2027
5. Leading National Markets: Sales Outlooks, 2017-2027
5.1 IBD Drugs - Leading National Markets 2016
5.2 The US IBD Drug Market, 2017-2017 – The World Leader
5.3 The Japanese IBD Drug Market, 2017-2027 – Growing Significantly?
5.4 The EU-5 IBD Drug Market, 2017-2027 – Driven by the UK
5.4.1 The German IBD Drug Market, 2017-2027
5.4.2 The French IBD Drug Market, 2017-2027
5.4.3 The UK IBD Drug Market, 2017-2027
5.4.4 The Spanish IBD Drug Market, 2017-2027
5.4.5 The Italian IBD Drug Market, 2017-2027
5.5 IBD Drug Markets in BRIC Countries – Taking More Market Share
5.5.1 The Brazilian IBD Drug Market, 2017-2027
5.5.2 The Russian IBD Drug Market, 2017-2027
5.5.3 The Indian Drug Market, 2017-2027
5.5.4 The Chinese IBD Drug Market, 2017-2027

5. www.visiongain.com
Contents
6. The R&D Pipeline for Inflammatory Bowel Disease, 2016
6.1 Top Marketed and pipeline products – Launch dates and Patent expiry
6.2 Interleukin (IL) Inhibitors – One of the Main Areas of Innovation
6.2.1 CyCol (Sigmoid Pharma)
6.2.2 PF-04236921 (Pfizer)
6.2.3 QAX 576 (Novartis)
6.2.4 TNF Kinoid (Neovacs)
6.2.5 Vidofludimus (4SC) – Suspended
6.2.6 Stelara (Ustekinumab, CNTO 1275, Janssen Biotech)
6.3 Cell-Adhesion Molecule (CAM) Inhibitors – A Promising Avenue
6.3.1 AJG 511 (Ajinomoto Pharmaceutical Co.)
6.3.2 AJM 300 (Ajinomoto Pharmaceuticals)
6.3.3 MEDI 7183/AMG 181 (AstraZeneca)
6.3.4 Etrolizumab (Roche)
6.3.5 PF-00547659 (Pfizer)
6.3.6 Alicaforsen (ISIS 2302, Atlantic Healthcare)
6.4 TNF-α Inhibitors – a Specific Target
6.4.1 AVX-470 (Avaxia Biologics)
6.4.2 Ozoralizumab (ALX-0061, Ablynx)
6.5 Stem Cell Therapies – Basis for a Cure?
6.5.1 Ovasave (TxCell)
6.5.2 MultiStem (Athersys and Pfizer)
6.5.3 Prochymal (Remestemcel-L, Osiris Therapeutics)
6.5.4 Cx601 (TiGenix)
6.6 JAK Inhibitors – New Target Pathway
6.6.1 JNJ-54781532 (Janssen)
6.6.2 Xeljanz, (Tofacitinib, CP-690550, Pfizer)
6.7 Toll-like Receptor Agonists
6.7.1 BL-7040 (BioLineRX)
6.7.2 Kappaproct (InDex Pharmaceuticals)

6. www.visiongain.com
Contents
6.8 Other Classes of Agent
6.8.1 Trichuris suis ova (CNDO-201, Coronado Biosciences)
6.8.2 GLPG0974 (Galapagos)
6.8.3 RPC1063 (Receptos/now Celgene)
6.8.4 SGX203 (Soligenix)
6.8.5 Mongersen (GED-0301, Celgene)
6.8.6 Tetomilast (OPC-6535, Otsuka)
6.8.7 Laquinimod (Active Biotech)
6.8.8 RHB-104 (RedHill Biopharma)
6.8.9 Ozanimod (Celgene)
6.8.10 GED-0301 (Celgene)
6.9 Biosimilar Candidates – Promising Competitors of Leading Biologics
6.9.1 Adalimumab Biosimilars
6.9.2 Infliximab Biosimilars
7. Drivers and Restraints in the Inflammatory Bowel Disease Drug
Industry and Market, 2016
7.1 SWOT and STEP Analyses of the IBD Drugs Market
7.2 What Factors Will Stimulate the IBD Market?
7.2.1 Increasing Disease Incidence in Most National Markets
7.2.2 Better Diagnosis – Early Referrals
7.2.3 Delivery Systems Improve Existing Drugs
7.2.4 Biological Drugs – Driving the Market Significantly
7.2.5 Socioeconomic Costs of IBD
7.3 What Factors Will Restrain the Market?
7.3.1 Lack of Understanding of Disease Aetiology
7.3.2 Compliance – Frequent Dosing is Inconvenient
7.3.3 Limitations of Biologics – Side Effect Profiles
7.3.4 The Possible Development of Alternative Treatments
7.3.5 Surgery – Treatment for Recalcitrant IBD

7. www.visiongain.com
Contents
7.3.6 Health Care Cost Containment
8. Leading Companies in the IBD Pharmaceuticals Market, 2016
8.1 The Largest Companies by Revenue
8.1.1 AbbVie
8.1.2 Janssen Biotech
8.1.3 Allergan
8.1.4 Shire Pharmaceuticals
9. Conclusions of the Study
9.1 The IBD Drugs Market Will Expand from 2017 to 2027
9.2 Aminosalicylates and Other Non-Biologic Treatments
9.3 Biological Treatments Dominate the Market
9.4 Improvements Needed in IBD Therapy
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form
List of Tables
Table 2.1 Differentiating Crohn’s Disease and Ulcerative Colitis
Table 2.2 Worldwide Prevalence Rates for IBD, 2016
Table 2.3 Worldwide Incidence Rates for IBD, 2016
Table 2.4 Geographical Variations in the Incidence of IBD, 2016
Table 2.5 Other Drug Types Used to Treat IBD, 2016
Table 2.6 Treatment Protocol for IBD, 2016
Table 3.1 Global IBD Drug Sales ($m), Annual Growth Rates (%) and Market
Shares (%) by Segment, 2016 and 2017
Table 3.2 Global IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR
(%), 2016-2027

8. www.visiongain.com
Contents
Table 3.3 Global IBD Drug Forecast by Drug Category: Revenues ($m), AGR (%),
CAGR (%), 2016-2027
Table 3.4 Global IBD Drug Market Drivers and Restraints 2017-2027
Table 3.5 Global Biologics Forecast for IBD Market: Revenues ($m), AGR (%),
CAGR (%), 2016-2027
Table 3.6 Global Biologic Therapies Drivers and Restraints, 2017-2027
Table 3.7 Global Aminosalicylates Forecast for IBD Market: Revenues ($m), AGR
(%), CAGR (%), 2016-2027
Table 3.8 Global Aminosalicylates Drivers and Restraints, 2017-2027
Table 3.9 Global Antibiotics Forecast for IBD Market: Revenues ($m), AGR (%),
CAGR (%), 2016-2027
Table 3.10 Global Antibiotics Drivers and Restraints, 2017-2027
Table 3.11 Global Corticosteroids Forecast for IBD Market: Revenues ($m), AGR
(%), CAGR (%), 2016-2027
Table 3.12 Global Corticosteroids Drivers and Restraints, 2017-2027
Table 3.13 Global Immunomodulators Forecast for IBD Market: Revenues ($m),
AGR (%), CAGR (%), 2016-2027
Table 3.14 Global Immunomodulators Drivers and Restraints, 2017-2027
Table 4.1 Leading IBD Treatments by Revenue ($m), 2016
Table 4.2 Leading IBD Medicines: Revenue Forecasts ($m), AGR (%), 2016-2027
Table 4.3 World Humira Revenue Forecast: Revenues ($m), AGR (%), CAGR (%),
2016-2027
Table 4.4 Drivers and Restraints for Humira, 2017-2027
Table 4.5 World Remicade Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-
2027
Table 4.6 Drivers and Restraints for Remicade, 2017-2027
Table 4.7 World Asacol Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-
2027
Table 4.8 Drivers and Restraints for Asacol, 2017-2027
Table 4.9 World Pentasa Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-
2027

9. www.visiongain.com
Contents
Table 4.10 Drivers and Restraints for Pentasa, 2017-2027
Table 4.11 World Lialda Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-
2027
Table 4.12 Drivers and Restraints for Lialda, 2017-2027
Table 4.13 World Tysabri Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-
2027
Table 4.14 Drivers and Restraints for Tysabri, 2017-2027
Table 4.15 World Xifaxan Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-
2027
Table 4.16 Drivers and Restraints for Xifaxan, 2017-2027
Table 4.17 World Cimzia Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-
2027
Table 4.18 Drivers and Restraints for Cimzia, 2017-2027
Table 4.19 World Entocort Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-
2027
Table 4.20 Drivers and Restraints for Entocort, 2017-2027
Table 4.21 World Neoral Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-
2027
Table 4.22 Drivers and Restraints for Neoral, 2017-2027
Table 4.23 World Medrol Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-
2027
Table 4.24 Drivers and Restraints for Medrol, 2017-2027
Table 4.25 World Canasa Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-
2027
Table 4.26 Drivers and Restraints for Canasa, 2017-2027
Table 4.27 World Apriso Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-
2027
Table 4.28 Drivers and Restraints for Apriso, 2017-2027
Table 4.29 World Azulfidine Forecast: Revenues ($m), AGR (%), CAGR (%),
2016-2027
Table 4.30 Drivers and Restraints for Azulfidine, 2017-2027

10. www.visiongain.com
Contents
Table 4.31 World Entyvio Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-
2027
Table 4.32 Drivers and Restraints for Entyvio, 2017-2027
Table 4.33 World Simponi Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-
2027
Table 4.34 Drivers and Restraints for Simponi, 2017-2027
Table 4.35 World Uceris Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-
2027
Table 4.36 Drivers and Restraints for Uceris, 2017-2027
Table 5.1 IBD Drug Revenues ($m) by Leading Country, 2016
Table 5.2 US IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%),
2016-2027
Table 5.3 Japanese IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR
(%), 2016-2027
Table 5.4 EU5 IBD Drug Market Forecasts: Revenues ($m), AGR (%), CAGR (%),
2016-2021
Table 5.5 EU5 IBD Drug Market Forecasts: Revenues ($m), AGR (%), CAGR (%),
2021-2027
Table 5.6 German IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR
(%), 2016-2027
Table 5.7 French IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR
(%), 2016-2027
Table 5.8 UK IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%),
2016-2027
Table 5.9 Spanish IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR
(%), 2016-2027
Table 5.10 Italian IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR
(%), 2016-2027
Table 5.11 BRIC IBD Drug Market Forecasts: Revenues ($m), AGR (%), CAGR
(%), 2016-2021

11. www.visiongain.com
Contents
Table 5.12 BRIC IBD Drug Market Forecasts: Revenues ($m), AGR (%), CAGR
(%), 2021-2027
Table 5.13 Brazilian IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR
(%), 2016-2027
Table 5.14 Russian IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR
(%), 2016-2027
Table 5.15 Indian IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR
(%), 2016-2027
Table 5.16 Chinese IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR
(%), 2016-2027
Table 6.1 Key Patent dates for marketed and pipeline products
Table 6.2 Selected IL Inhibitors in Clinical Development, 2016
Table 6.3 Selected CAM Inhibitors in Clinical Development, 2016
Table 6.4 Selected TNF-α Inhibitors in Clinical Development, 2016
Table 6.5 Selected Stem Cell Therapies in Clinical Development, 2016
Table 6.6 Selected JAK Inhibitors in Clinical Development, 2016
Table 6.7 Selected Toll-like Receptor Agonist in Clinical Development, 2016
Table 6.8 Selected Other Classes in Clinical Development, 2016
Table 7.1 Strengths, Weaknesses, Opportunities and Threats in the IBD Drug
Market, 2016
Table 7.2 Social, Technological, Economic and Political Forces on the IBD Drug
Market, 2016
Table 8.1 Top 4 Companies for IBD Drugs: Revenues ($m) and Market Shares
(%), 2016
Table 8.2 AbbVie Revenues ($m) and Market Share (%), 2016
Table 8.3 Janssen Biotech Revenues ($m) and Market Share (%), 2016
Table 8.4 Allergan Revenues ($m) and Market Share (%), 2016
Table 8.5 Shire Revenues ($m) and Market Share (%), 2016
Table 9.1 Global IBD Revenue Forecasts ($m), CAGR (%) and Market Share (%)
by Product Category, 2016, 2021, 2027

12. www.visiongain.com
Contents
Table 9.2 Global IBD Revenue Forecasts ($m), CAGR (%) and Market Shares (%)
by Region, 2016, 2021, 2027

13. www.visiongain.com
Contents
List of Figures
Figure 1.1 Inflammatory Bowel Disease Market Segmentation, 2016
Figure 3.1 World IBD Drugs Market Shares by Product Type (%), 2016
Figure 3.2 Global IBD Drug Market Forecast ($m), 2016-2027
Figure 3.3 World IBD Drugs Market Shares by Product Type (%), 2027
Figure 3.4 Global Biologics Forecast for IBD Market ($m), 2016-2027
Figure 3.5 Global Aminosalicylates Forecast for IBD Market ($m), 2016-2027
Figure 3.6 Global Antibiotics Forecast for IBD Market ($m), 2016-2027
Figure 3.7 Global Corticosteroids Forecast for IBD Market ($m), 2016-2027
Figure 3.8 Global Immunomodulators Forecast for IBD Market ($m), 2016-2027
Figure 4.1 World Humira Revenue Forecast ($m), 2016-2027
Figure 4.2 World Remicade Forecast ($m), 2016-2027
Figure 4.3 World Asacol Forecast ($m), 2016-2027
Figure 4.4 World Pentasa Forecast ($m), 2016-2027
Figure 4.5 World Lialda Forecast ($m), 2016-2027
Figure 4.6 World Tysabri Forecast ($m), 2016-2027
Figure 4.7 World Xifaxan Forecast ($m), 2016-2027
Figure 4.8 World Cimzia Forecast ($m), 2016-2027
Figure 4.9 World Entocort Forecast ($m), 2016-2027
Figure 4.10 World Neoral Forecast ($m), 2016-2027
Figure 4.11 World Medrol Forecast ($m), 2016-2027
Figure 4.12 World Canasa Forecast ($m), 2016-2027
Figure 4.13 World Apriso Forecast ($m), 2016-2027
Figure 4.14 World Azulfidine Forecast ($m), 2016-2027
Figure 4.15 World Entyvio Forecast ($m), 2016-2027
Figure 4.16 World Simponi Forecast ($m), 2016-2027
Figure 4.17 World Uceris Forecast ($m), 2016-2027
Figure 5.1 Global IBD Drug Market by Leading Country (%), 2016
Figure 5.2 Global IBD Drug Market by Leading Country (%), 2027
Figure 5.3 US IBD Drug Market Forecast ($m), 2016-2027

14. www.visiongain.com
Contents
Figure 5.4 Japanese IBD Drug Market Forecast ($m), 2016-2027
Figure 5.5 EU5 IBD Drug Market Forecasts ($m), 2016-2027
Figure 5.6 German IBD Drug Market Forecast ($m), 2016-2027
Figure 5.7 French IBD Drug Market Forecast ($m), 2016-2027
Figure 5.8 UK IBD Drug Market Forecast ($m), 2016-2027
Figure 5.9 Spanish IBD Drug Market Forecast ($m), 2016-2027
Figure 5.10 Italian IBD Drug Market Forecast ($m), 2016-2027
Figure 5.11 BRIC IBD Drug Market Forecasts ($m), 2016-2027
Figure 5.12 Brazilian IBD Drug Market Forecast ($m), 2016-2027
Figure 5.13 Russian IBD Drug Market Forecast ($m), 2016-2027
Figure 5.14 Indian IBD Drug Market Forecast ($m), 2016-2027
Figure 5.15 Chinese IBD Drug Market Forecast ($m), 2016-2027
Figure 8.1 Top Producers of IBD Drugs: Market Shares (%), 2016
Figure 8.2 AbbVie Assets – Marketed and Pipeline 2016
Figure 8.3 AbbVie Deals and Partnerships 2011 - 2016
Figure 8.4 Janssen Assets – Marketed and Pipeline 2016
Figure 8.5 Janssen – Deals and Partnerships 2011 - 2016
Figure 8.6 Allergan Assets – Marketed and Pipeline 2016
Figure 8.7 Allergan – Deals and Partnerships 2011 - 2016
Figure 8.8 Shire Assets – Marketed and Pipeline 2016
Figure 8.9 Shire – Deals and Partnerships 2011 - 2016

15. www.visiongain.com
Contents
List of Companies Mentioned in the Report
4SC
Abbott Laboratories
AbbVie
Ablynx
Actavis
Active Biotech
Ajinomoto
Allergan
Almirall
Amgen
Aptalis Pharmaceuticals
Astellas
AstraZeneca
Athersys
Atlantic Healthcare
Avaxia Biologics
BioLineRx
Biosafe
Boehringer Ingelheim
Calico
Celgene
Celltrion
Centocor Ortho Biotech
Coherus Biosciences
Coronado Biosciences
Cosmo Pharmaceuticals
Dr. Falk Pharma
Eddingpharm
Elan Pharmaceuticals
Epirus Biopharmaceuticals

16. www.visiongain.com
Contents
Ferring
Forest Laboratories
Galapagos
Giaconda
Google
Harbor Biosciences
Hospira
InDex Pharmaceuticals
Infinity Pharmaceuticals
Isis Pharmaceuticals
Janssen Biotech
Johnson & Johnson
LG Sciences
MedImmune
Mochida
Mutare Health
Mylan Pharmaceuticals
Neovacs
Nisshin Kyorin
Nogra Pharma
Novartis
Oncobiologics
Ortho Biotech
Osiris Therapeutics
Otsuka
Ovamed
Palau Pharma
Pendopharm
Perrigo
Pfizer
Pharmascience

17. www.visiongain.com
Contents
Pluristem Therapeutics
Quest Diagnostics
Ranbaxy Laboratories
Receptos
RedHill Biopharma
Reliance Life Sciences
Roche
Salix Pharmaceuticals
Sandoz
Sanofi
Santarus
Sequella
Shire Pharmaceuticals
Sigmoid Pharma
Soligenix
SonarMD
Takeda Pharmaceuticals
Teva Pharmaceutical Industries
TiGenix
Toray Industries
TxCell
UCB
Valeant
Warner Chilcott
Zydus Cadila
List of Organisations Mentioned in the Report
Center for Human Disease Research, Leiden
Centrale Commissie Mensgebonden Onderzoek (CCMO)
Centres for Disease Control and Prevention (US)
Crohn’s and Colitis Foundation of Canada

18. www.visiongain.com
Contents
European Medicines Agency (EMA)
Food and Drug Administration (US FDA)
Georgia State University
Hebrew University of Jerusalem
Institut National de la Santé et de la Recherche Médicale (INSERM)
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
Karolinska Institute
National Health Service (UK NHS)
National Institute for Health and Care Excellence (UK NICE)
National Institutes of Health (US NIH)
Servicio Sanitario Nazionale (SSN, Italy)
The Crohn’s and Colitis UK Foundation
The European Federation of Crohn's and Ulcerative Colitis Associations

19. Page 60www.visiongain.com
Global Inflammatory Bowel Diseases (IBD) Drug
Market Forecast 2017-2027: Aminosalicylates,
Antibiotics, Corticosteroids, Immunomodulators,
Biologics, Crohn’s Disease, Ulcerative Colitis
Table 3.12 Global Corticosteroids Drivers and Restraints, 2017-2027
The consensus regarding treatment with these agents is that they should be tapered once
remission has been induced. Corticosteroids do not have a role in maintaining remission.
Patients who are concerned about immunosuppressive therapies, including immunomodulators or
anti–tumour necrosis factor (TNF) agents, should be educated about the potential greater
incidence of complications occurring with long-term steroid use and with undertreated disease.
Patients with prolonged use of steroids may also require ophthalmologic examination because of
the risk of development of glaucoma and cataracts.
Periodic assessment of bone mineral density is recommended for patients taking steroids for more
than 3 months. Agents used for osteoporosis prevention and treatment are useful for preventing
the bone loss associated with corticosteroid use.
Intravenous corticosteroids are often used for patients who are severely ill and hospitalized; few
data have been published on the optimum dosage of IV or oral corticosteroids. The upper end of
dosing generally includes IV methylprednisolone at 20 mg every 6 hours or IV hydrocortisone at
100 mg every 8 hours. Typically, once a clinical response is observed (usually within 3-5 days), the
dose of the IV corticosteroid can be tapered. Before hospital discharge, conversion to an oral
corticosteroid is made with dosage tapering in an outpatient setting.
• Act rapidly to control
symptoms, hence considered
to be very effective in this
capacity
• Can be administered through
various different routes,
depending on patient’s
condition
Drivers Restraints
• Only used to control flare ups
of IBD, and not used as a
maintenance therapy
• Associated with reported side
effects when used over long
periods of time
Source: visiongain 2017

20. Page 62www.visiongain.com
Global Inflammatory Bowel Diseases (IBD) Drug
Market Forecast 2017-2027: Aminosalicylates,
Antibiotics, Corticosteroids, Immunomodulators,
Biologics, Crohn’s Disease, Ulcerative Colitis
Table 3.13 Global Immunomodulators Forecast for IBD Market:
Revenues ($m), AGR (%), CAGR (%), 2016-2027
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Revenue($m) 77 74 70 65 60 55 50 45 38 32 27 23
AGR (%) -4 -4 -5 -7 -8 -8 -9 -10 -16 -16 -16 -15
CAGR (%) -6.5 -13.5
CAGR (%) -10.4
0
10
20
30
40
50
60
70
80
90
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Revenue($m)
Figure 3.8 Global Immunomodulators Forecast for IBD Market ($m), 2016-
2027
Source: visiongain 2017
Source: visiongain 2017. CAGR values are for the periods 2016-2021, 2021-2027 and 2016-2027

21. Page 133www.visiongain.com
Global Inflammatory Bowel Diseases (IBD) Drug
Market Forecast 2017-2027: Aminosalicylates,
Antibiotics, Corticosteroids, Immunomodulators,
Biologics, Crohn’s Disease, Ulcerative Colitis
The Italian market is restricted by the poor economic environment. Servicio Sanitario Nazionale
(SSN), the Italian healthcare system (a universal healthcare system similar to the UK’s National
Health Service), is challenged by decreasing budgets, increased focus on chronic diseases and
diseases related to the elderly. Austerity measures implemented in June 2010 introduced
reimbursement limits for generics, price cuts, requirements for doctors to prescribe the cheapest
generic where possible, a reduction in the pharmacy profit margin of the end price of a drug, and a
levy on drug manufacturers set at 1.83% of the price of the drug to be paid to regional health
authorities. Further regulation was passed in March 2012, and visiongain believes more changes
are likely to follow in the next ten years as the Italian government struggles to contain healthcare
spending.
5.5 IBD Drug Markets in BRIC Countries – Taking More
Market Share
The BRIC nations had a combined IBD drug market value of $949m in 2016, or 11% of the global
market. In addition, the market in these countries is expected to grow at a comparable rate to other
0
100
200
300
400
500
600
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Revenue($m)
Figure 5.10 Italian IBD Drug Market Forecast ($m), 2016-2027
Source: visiongain 2017